Antibodies against HSV-1 and Curli Show the Highest Correlation in Parkinson’s Disease Patients in Comparison to Healthy Controls
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Study Population and Blood Collection
4.2. Peptides
4.3. Enzyme-Linked Immunosorbent Assay (ELISA)
4.4. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gouda, N.A.; Elkamhawy, A.; Cho, J. Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update. Biomedicines 2022, 10, 371. [Google Scholar] [CrossRef] [PubMed]
- Shen, T.; Yue, Y.; He, T.; Huang, C.; Qu, B.; Lv, W.; Lai, H.-Y. The Association Between the Gut Microbiota and Parkinson’s Disease, a Meta-Analysis. Front. Aging Neurosci. 2021, 13, 636545. [Google Scholar] [CrossRef]
- Li, D.; Ren, T.; Li, H.; Liao, G.; Zhang, X. Porphyromonas gingivalis: A key role in Parkinson’s disease with cognitive impairment? Front. Neurol. 2022, 13, 945523. [Google Scholar] [CrossRef]
- Barnhart, M.M.; Chapman, M.R. Curli Biogenesis and Function. Annu. Rev. Microbiol. 2006, 60, 131–147. [Google Scholar] [CrossRef] [Green Version]
- Han, M.N.; Finkelstein, D.I.; McQuade, R.M.; Diwakarla, S. Gastrointestinal Dysfunction in Parkinsons Disease: Current and Potential Therapeutics. J. Pers. Med. 2022, 12, 144. [Google Scholar] [CrossRef]
- Lotz, S.K.; Blackhurst, B.M.; Reagin, K.L.; Funk, K.E. Microbial Infections Are a Risk Factor for Neurodegenerative Diseases. Front. Cell. Neurosci. 2021, 15, 691136. [Google Scholar] [CrossRef] [PubMed]
- Smeyne, R.J.; Noyce, A.J.; Byrne, M.; Savica, R.; Marras, C. Infection and Risk of Parkinson’s Disease. J. Park. Dis. 2021, 11, 31–43. [Google Scholar] [CrossRef]
- Arru, G.; Caggiu, E.; Paulus, K.; Sechi, G.P.; Mameli, G.; Sechi, L.A. Is there a role for Mycobacterium avium subspecies paratuberculosis in Parkinson’s disease? J. Neuroimmunol. 2016, 293, 86–90. [Google Scholar] [CrossRef]
- Caggiu, E.; Paulus, K.; Galleri, G.; Arru, G.; Manetti, R.; Sechi, G.P.; Sechi, L.A. Homologous HSV-1 and alpha-synuclein peptides stimulate a T cell response in Parkinson’s disease. J. Neuroimmunol. 2017, 310, 26–31. [Google Scholar] [CrossRef]
- Zhang, N.; Zuo, Y.; Jiang, L.; Peng, Y.; Huang, X.; Zuo, L. Epstein-Barr Virus and Neurological Diseases. Front. Mol. Biosci. 2022, 8, 816098. [Google Scholar] [CrossRef] [PubMed]
- Patrick, K.L.; Bell, S.L.; Weindel, C.G.; Watson, R.O. Exploring the “Multiple-Hit Hypothesis” of Neurodegenerative Disease: Bacterial Infection Comes Up to Bat. Front. Cell. Infect. Microbiol. 2019, 9, 138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vidović, M.; Rikalovic, M.G. Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches. Cells 2022, 11, 1732. [Google Scholar] [CrossRef] [PubMed]
- Fasano, A.; Visanji, N.P.; Liu, L.W.C.; Lang, A.E.; Pfeiffer, R.F. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015, 14, 625–639. [Google Scholar] [CrossRef]
- Visanji, N.P.; Marras, C.; Hazrati, L.-N.; Liu, L.W.C.; Lang, A.E. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson’s disease biomarker. Mov. Disord. 2014, 29, 444–450. [Google Scholar] [CrossRef] [PubMed]
- Miller, A.L.; Bessho, S.; Grando, K.; Tükel, Ç. Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Front. Immunol. 2021, 12, 638867. [Google Scholar] [CrossRef]
- Tükel, Ç.; Nishimori, J.H.; Wilson, R.P.; Winter, M.G.; Keestra, A.M.; Van Putten, J.P.M.; Bäumler, A.J. Toll-like receptors 1 and 2 cooperatively mediate immune responses to curli, a common amyloid from enterobacterial biofilms. Cell. Microbiol. 2010, 12, 1495–1505. [Google Scholar] [CrossRef] [Green Version]
- Tursi, S.A.; Tükel, Ç. Curli-containing enteric biofilms inside and out: Matrix composition, immune recognition, and disease implications. Microbiol. Mol. Biol. Rev. 2018, 82, e00028-18. [Google Scholar] [CrossRef] [Green Version]
- Noli, M.; Meloni, G.; Manca, P.; Cossu, D.; Palermo, M.; Sechi, L.A. HERV-W and Mycobacterium avium subspecies paratuberculosis Are at Play in Pediatric Patients at Onset of Type 1 Diabetes. Pathogens 2021, 10, 1135. [Google Scholar] [CrossRef]
- Woulfe, J.M.; Duke, R.; Middeldorp, J.M.; Stevens, S.; Vervoort, M.; Hashimoto, M.; Masliah, E.; Chan, P.; Di Monte, D.A.; Langston, J.W.; et al. Absence of elevated anti–α-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 2002, 58, 1435. [Google Scholar] [CrossRef]
- Smith, L.M.; Schiess, M.C.; Coffey, M.P.; Klaver, A.C.; Loeffler, D.A. α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls. PLoS ONE 2012, 7, e52285. [Google Scholar] [CrossRef]
- Yanamandra, K.; Gruden, M.A.; Casaite, V.; Meskys, R.; Forsgren, L.; Morozova-Roche, L.A. α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson’s Disease Patients. PLoS ONE 2011, 6, e18513. [Google Scholar] [CrossRef]
- Li, Q.-X.; Mok, S.S.; Laughton, K.M.; McLean, C.A.; Cappai, R.; Masters, C.L.; Culvenor, J.G.; Horne, M.K. Plasma α-synuclein is decreased in subjects with Parkinson’s disease. Exp. Neurol. 2007, 204, 583–588. [Google Scholar] [CrossRef] [PubMed]
- Sampson, T.R.; Debelius, J.W.; Thron, T.; Janssen, S.; Shastri, G.G.; Ilhan, Z.E.; Challis, C.; Schretter, C.E.; Rocha, S.; Gradinaru, V.; et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell 2016, 6, 1469–1480. [Google Scholar] [CrossRef] [Green Version]
- Pachucki, R.J.; Corradetti, C.; Kohler, L.; Ghadiali, J.; Gallo, P.M.; Nicastro, L.; Tursi, S.A.; Gallucci, S.; Tükel, Ç.; Caricchio, R. Persistent Bacteriuria and Antibodies Recognizing Curli/eDNA Complexes From Escherichia coli Are Linked to Flares in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020, 72, 1872–1881. [Google Scholar] [CrossRef] [PubMed]
- Martínez-García, M.; Hernández-Lemus, E. Periodontal Inflammation and Systemic Diseases: An Overview. Front. Physiol. 2021, 12, 709438. [Google Scholar] [CrossRef] [PubMed]
- Makiura, N.; Ojima, M.; Kou, Y.; Furuta, N.; Okahashi, N.; Shizukuishi, S.; Amano, A. Relationship of Porphyromonas gingivalis with glycemic level in patients with type 2 diabetes following periodontal treatment. Oral Microbiol. Immunol. 2008, 23, 348–351. [Google Scholar] [CrossRef]
- Blasco-Baque, V.; Garidou, L.; Pomié, C.; Escoula, Q.; Loubieres, P.; Le Gall-David, S.; Lemaitre, M.; Nicolas, S.; Klopp, P.; Waget, A.; et al. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut 2017, 66, 872–885. [Google Scholar] [CrossRef] [Green Version]
- Dominy, S.S.; Lynch, C.; Ermini, F.; Benedyk, M.; Marczyk, A.; Konradi, A.; Nguyen, M.; Haditsch, U.; Raha, D.; Griffin, C.; et al. Porphyromonas gingivalis in Alzheimers disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 2019, 5, eaau3333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okada, M.; Kobayashi, T.; Ito, S.; Yokoyama, T.; Abe, A.; Murasawa, A.; Yoshie, H. Periodontal Treatment Decreases Levels of Antibodies to Porphyromonas gingivalis and Citrulline in Patients With Rheumatoid Arthritis and Periodontitis. J. Periodontol. 2013, 84, e74–e84. [Google Scholar] [CrossRef] [PubMed]
- Jasemi, S.; Erre, G.L.; Cadoni, M.L.; Bo, M.; Sechi, L.A. Humoral Response to Microbial Biomarkers in Rheumatoid Arthritis Patients. J. Clin. Med. 2021, 10, 5153. [Google Scholar] [CrossRef]
- Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. Links between atherosclerotic and periodontal disease. Exp. Mol. Pathol. 2016, 100, 220–235. [Google Scholar] [CrossRef]
- Deshpande, R.G.; Khan, M.; Genco, C.A. Invasion strategies of the oral pathogen Porphyromonas gingivalis: Implications for cardiovascular disease. Invasion Metastasis 1998, 18, 57–69. [Google Scholar] [CrossRef] [PubMed]
- Díaz-Zúñiga, J.; Muñoz, Y.; Melgar-Rodríguez, S.; More, J.; Bruna, B.; Lobos, P.; Monasterio, G.; Vernal, R.; Paula-Lima, A. Serotype b of Aggregatibacter actinomycetemcomitans triggers pro-inflammatory responses and amyloid beta secretion in hippocampal cells: A novel link between periodontitis and Alzheimer’s disease? J. Oral Microbiol. 2019, 11, 1586423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agostini, S.; Mancuso, R.; Costa, A.S.; Citterio, L.A.; Guerini, F.R.; Meloni, M.; Navarro, J.; Clerici, M. A Possible Role for HSV-1-Specific Humoral Response and PILRA rs1859788 Polymorphism in the Pathogenesis of Parkinson’s Disease. Vaccines 2021, 9, 686. [Google Scholar] [CrossRef] [PubMed]
- Ramakrishna, C.; Mendonca, S.; Ruegger, P.M.; Kim, J.H.; Borneman, J.; Cantin, E.M. Herpes simplex virus infection, Acyclovir and IVIG treatment all independently cause gut dysbiosis. PLoS ONE 2020, 15, e0237189. [Google Scholar] [CrossRef] [PubMed]
- Woulfe, J.; Gray, M.T.; Ganesh, M.S.; Middeldorp, J.M. Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein. Neurol. Neuroimmunol. Neuroinflamm. 2016, 3, e239. [Google Scholar] [CrossRef] [Green Version]
- Woulfe, J.M.; Gray, M.T.; Gray, D.A.; Munoz, D.G.; Middeldorp, J.M. Hypothesis: A role for EBV-induced molecular mimicry in Parkinson’s disease. Park. Relat. Disord. 2014, 20, 685–694. [Google Scholar] [CrossRef] [PubMed]
- Tuck, M.K.; Chan, D.W.; Chia, D.; Godwin, A.K.; Grizzle, W.E.; Krueger, K.E.; Rom, W.; Sanda, M.; Sorbara, L.; Stass, S.; et al. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J. Proteome Res. 2009, 8, 113–117. [Google Scholar] [CrossRef] [Green Version]
- Mameli, G.; Cocco, E.; Frau, J.; Marrosu, M.G.; Sechi, L.A. Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients. Sci. Rep. 2016, 6, 22401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Epitope Sequence | Epitope Position | |
---|---|---|
α-syn100–114 | LGKNEEGAPQEGILE | 100–114 |
Curli133–141 | NSSVNVTQV | 133–141 |
UI4222–36 | LGQPEEGAPCQVVLQ | 22–36 |
RgpA800–812 | ADPVVTTQNIIVT | 800–812 |
Kpg328–339 | VTDLYYSAVDGD | 328–339 |
LtxA1429–445 | AWENKYGKNTFENGYDA | 429–445 |
LtxA264–80 | TALIKAAQKLGIEVYHE | 64–80 |
MAP3865c125–133 | MIAVALAGL | 125–133 |
MAP1,4-a-gbp157–173 | GTVELLGGPLAHPFQPL | 157–173 |
MAP_402718–32 | AVVPVLAYAAARLL | 18–32 |
EBNA1400–413 | PGRRPFFHPVGEAD | 400–413 |
BOLF1305–320 | AAVPVLAFDAARLRLLE | 305–320 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jasemi, S.; Paulus, K.; Noli, M.; Simula, E.R.; Ruberto, S.; Sechi, L.A. Antibodies against HSV-1 and Curli Show the Highest Correlation in Parkinson’s Disease Patients in Comparison to Healthy Controls. Int. J. Mol. Sci. 2022, 23, 14816. https://doi.org/10.3390/ijms232314816
Jasemi S, Paulus K, Noli M, Simula ER, Ruberto S, Sechi LA. Antibodies against HSV-1 and Curli Show the Highest Correlation in Parkinson’s Disease Patients in Comparison to Healthy Controls. International Journal of Molecular Sciences. 2022; 23(23):14816. https://doi.org/10.3390/ijms232314816
Chicago/Turabian StyleJasemi, Seyedesomaye, Kai Paulus, Marta Noli, Elena Rita Simula, Stefano Ruberto, and Leonardo A. Sechi. 2022. "Antibodies against HSV-1 and Curli Show the Highest Correlation in Parkinson’s Disease Patients in Comparison to Healthy Controls" International Journal of Molecular Sciences 23, no. 23: 14816. https://doi.org/10.3390/ijms232314816